A detailed history of Hsbc Holdings PLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 9,088 shares of EXEL stock, worth $350,615. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,088
Previous 27,126 66.5%
Holding current value
$350,615
Previous $703,000 57.04%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$25.39 - $36.46 $457,984 - $657,665
-18,038 Reduced 66.5%
9,088 $302,000
Q3 2024

Nov 14, 2024

SELL
$21.96 - $27.6 $1.39 Million - $1.74 Million
-63,085 Reduced 69.93%
27,126 $703,000
Q2 2024

Aug 12, 2024

BUY
$20.34 - $23.73 $572,082 - $667,429
28,126 Added 45.3%
90,211 $2.03 Million
Q1 2024

May 15, 2024

BUY
$20.17 - $23.93 $335,346 - $397,860
16,626 Added 36.57%
62,085 $1.47 Million
Q4 2023

Feb 12, 2024

SELL
$19.25 - $24.13 $1.67 Million - $2.1 Million
-86,952 Reduced 65.67%
45,459 $1.09 Million
Q3 2023

Nov 13, 2023

BUY
$19.04 - $22.74 $1.57 Million - $1.87 Million
82,276 Added 164.11%
132,411 $2.89 Million
Q2 2023

Aug 11, 2023

BUY
$18.17 - $20.48 $36,485 - $41,123
2,008 Added 4.17%
50,135 $958,000
Q1 2023

May 15, 2023

SELL
$16.3 - $19.41 $2.55 Million - $3.03 Million
-156,321 Reduced 76.46%
48,127 $934,000
Q4 2022

Feb 14, 2023

BUY
$14.96 - $17.39 $97,449 - $113,278
6,514 Added 3.29%
204,448 $3.28 Million
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $2.45 Million - $3.47 Million
156,032 Added 372.37%
197,934 $3.14 Million
Q2 2022

Aug 11, 2022

BUY
$17.44 - $23.16 $250,874 - $333,156
14,385 Added 52.28%
41,902 $878,000
Q1 2022

May 16, 2022

BUY
$17.03 - $22.67 $188,300 - $250,662
11,057 Added 67.17%
27,517 $625,000
Q4 2021

Feb 11, 2022

SELL
$15.84 - $21.88 $237,821 - $328,506
-15,014 Reduced 47.7%
16,460 $300,000
Q3 2021

Nov 12, 2021

SELL
$16.3 - $21.14 $370,808 - $480,913
-22,749 Reduced 41.95%
31,474 $671,000
Q2 2021

Aug 13, 2021

BUY
$17.95 - $25.56 $452,214 - $643,933
25,193 Added 86.78%
54,223 $987,000
Q1 2021

May 14, 2021

BUY
$20.53 - $25.22 $214,066 - $262,968
10,427 Added 56.05%
29,030 $655,000
Q4 2020

Feb 12, 2021

SELL
$18.39 - $24.8 $177,481 - $239,344
-9,651 Reduced 34.16%
18,603 $373,000
Q3 2020

Nov 12, 2020

BUY
$20.67 - $26.94 $194,008 - $252,858
9,386 Added 49.75%
28,254 $692,000
Q2 2020

Aug 14, 2020

SELL
$16.46 - $27.42 $337,281 - $561,863
-20,491 Reduced 52.06%
18,868 $448,000
Q1 2020

May 15, 2020

BUY
$14.46 - $21.8 $28,515 - $42,989
1,972 Added 5.27%
39,359 $687,000
Q4 2019

Feb 14, 2020

BUY
$15.15 - $18.89 $566,413 - $706,240
37,387 New
37,387 $665,000
Q2 2019

Aug 13, 2019

SELL
$18.93 - $24.75 $1.11 Million - $1.45 Million
-58,755 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$19.6 - $24.76 $367,598 - $464,373
18,755 Added 46.89%
58,755 $1.4 Million
Q4 2018

Feb 13, 2019

SELL
$13.65 - $21.8 $1.47 Million - $2.35 Million
-107,865 Reduced 72.95%
40,000 $782,000
Q3 2018

Nov 13, 2018

BUY
$15.87 - $22.4 $2.35 Million - $3.31 Million
147,865 New
147,865 $2.62 Million
Q1 2018

May 11, 2018

SELL
$22.15 - $31.89 $2.88 Million - $4.14 Million
-129,871 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$24.23 - $30.93 $3.15 Million - $4.02 Million
129,871
129,871 $3.95 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $12.4B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.